BioWorld

Aug. 22, 2011

Macro Woes Could Impact Biotech Financing, M&A

The economic situation over the last month or so "reminds a lot of people of 2008 and I can understand why," said Andy Busch, global currency and public policy strategist for BMO Capital Markets, during a recent conference call. Read More

New Use for Cash? Amgen Gives NPS Royalty Advance

Up-Front Milestone Balance Shifting in Biotechs' Favor

Money Raised Year to Date

Money Raised By Biotech in 2011

Week in Review

Word on the Street

Week in Washington

Collaborations Between Biotechnology Companies And Government/Nonprofit Institutions: March 1 - August 19, 2011

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...

Flow Neuro wins FDA nod for at-home device for depression

BioWorld MedTech

Flow Neuroscience AB received U.S. FDA 510(k) approval for its Flow at-home brain-stimulation device to treat major depressive disorder. The wearable headset uses...